Skip to content
akaturk Academic measurement
Sign in Sign up

OpenAlex topic

HIV/AIDS drug development and treatment

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 1,158 works 30 author topics

Works

1,158 works

  1. Three Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B 2011
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.8%

    No abstract yet.

  2. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection 2018
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.8%

    No abstract yet.

  3. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection 2018
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.8%

    No abstract yet.

  4. ABT 450 Ritonavir Ombitasvir and Dasabuvir Achieves 97 and 100 Sustained Virologic Response With or Without Ribavirin in Treatment Experienced Patients With HCV Genotype 1b Infection 2014
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.8%

    BACKGROUND & AIMS: The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside polymerase inhibitor), and ribavirin has shown efficacy in patients with hepatitis C virus (HCV) genotype 1b infection-the most prevalent subgenotype worldwide. We ev…

  5. Combination of Tenofovir Disoproxil Fumarate and Peginterferon 2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B 2016
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.8%

    BACKGROUND & AIMS: Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated HBsAg loss in patients receiving the combination of tenofovir disoproxil fumarate (TDF) and peginterferon α-2a (peginterferon) for a finit…

  6. Seven Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection 2015
    YÖKSİS SJR Q2 JCR Q3 OpenAlex top 1% OpenAlex 99.7%

    BACKGROUND: Long-term tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B (CHB) is associated with sustained viral suppression and regression of fibrosis and cirrhosis at year 5 (240 weeks) and no TDF resistance through 6 years (288 weeks). AIM: We assessed the efficacy, safety, and resistance of TDF…

  7. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection a proof of concept randomised double blind placebo controlled phase 2A trial 2015
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.3%

    BACKGROUND: Therapies for chronic hepatitis delta virus (HDV) infection are unsatisfactory. Prenylation is essential for HDV and inhibition abrogates HDV production in experimental models. In a proof-of-concept study, we aimed to assess the effect on HDV RNA levels, safety, and tolerability of the prenylation inhibito…

  8. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial 2015
    OpenAlex top 1% OpenAlex 99.3%

    No abstract yet.

  9. Intrinsic and Acquired Resistance to Methotrexate in Acute Leukemia 1996
    OpenAlex top 1% OpenAlex 99.3%

    Methotrexate, a folic acid antagonist, is used extensively not only for the treatment of cancer but also for the treatment of rheumatoid arthritis, psoriasis, and autoimmune disease and for the prevention of graft-versus-host disease after transplantation. The drug is also used as an abortifacient.1,2 Other folate ant…

  10. Synthesis of some novel thiourea derivatives obtained from 5 4 aminophenoxy methyl 4 alkyl aryl 2 4 dihydro 3H 1 2 4 triazole 3 thiones and evaluation as antiviral anti HIV and anti tuberculosis agents 2008
    YÖKSİS SJR Q1 JCR Q2 OpenAlex top 10% OpenAlex 92.5%

    No abstract yet.

  11. Synthesis of some novel thiourea derivatives obtained from 5 4 aminophenoxy methyl 4 alkyl aryl 2 4 dihydro 3H 1 2 4 triazole 3 thiones and evaluation as antiviral anti HIV and anti tuberculosis agents 2008
    YÖKSİS SJR Q1 JCR Q2 OpenAlex top 10% OpenAlex 92.5%

    No abstract yet.

  12. The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors 2012
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.9%

    Hepatitis C virus (HCV) infects over 170 million people worldwide and is the leading cause of chronic liver diseases, including cirrhosis, liver failure, and liver cancer. Available antiviral therapies cause severe side effects and are effective only for a subset of patients, though treatment outcomes have recently be…

Academicians

30 academicians